Key result
Oral sotalol rendered ventricular tachycardia non-inducible in 60% of patients, while 23% manifested at least one new morphology during electropharmacological testing.
Why the study?
Does oral sotalol alter induced ventricular tachycardia morphology during programmed stimulation in patients with coronary artery disease and sustained monomorphic ventricular tachycardia?
Observational (n=90)
Does oral sotalol alter induced ventricular tachycardia morphology during programmed stimulation in patients with coronary artery disease and sustained monomorphic ventricular tachycardia?
Answers are grounded in this paper and cite their sources.
Oral sotalol can induce new ventricular tachycardia morphologies during programmed stimulation, suggesting a potential proarrhythmic effect that may have implications for ICD programming and ablation procedures.
In 90 consecutive patients with coronary artery disease and sustained monomorphic ventricular tachycardia, who were treated with oral sotalol and underwent programmed stimulation to determine drug effectiveness, the influence of sotalol on induced ventricular tachycardia morphology was retrospectively examined. In 54 patients (60%) sotalol rendered the tachycardia non-inducible. However, contrary to drug-testing with class I antiarrhythmic agents, induction of multiple morphologies at baseline study did not predict failure of subsequent drug-testing with sotalol. In the remaining 36 patients (40%), in whom sotalol did not modify inducibility, 21 patients (i.e. a total of 23%) manifested at least one new morphology during electropharmacological testing on sotalol. This effect was independent of the degree of left ventricular dysfunction, infarct location and numbers of morphologies at baseline, but corresponded with drug-induced changes in refractoriness. This observation may be related to a proarrhythmic effect of sotalol. Slowing of ventricular tachycardia rate and changes in morphology may have implications in patients receiving implantable cardioverter-defibrillators or those undergoing ablative procedures.
No takes yet. Share an insight, caveat, or question.
Reisinger et al. (1995) conducted an observational in Coronary artery disease and sustained monomorphic ventricular tachycardia (n=90). Oral sotalol was evaluated on Non-inducibility of ventricular tachycardia. Oral sotalol rendered ventricular tachycardia non-inducible in 60% of patients, while 23% manifested at least one new morphology during electropharmacological testing.
Synapse has enriched 10 related papers. Consider them for comparative context: